Your browser is no longer supported. Please, upgrade your browser.
SBBP Strongbridge Biopharma plc weekly Stock Chart
SBBP [NASD]
Strongbridge Biopharma plc
Index- P/E- EPS (ttm)-0.77 Insider Own0.90% Shs Outstand56.11M Perf Week2.90%
Market Cap188.29M Forward P/E- EPS next Y-0.45 Insider Trans249.27% Shs Float38.09M Perf Month37.86%
Income-42.10M PEG- EPS next Q-0.14 Inst Own71.00% Short Float1.86% Perf Quarter-19.55%
Sales28.10M P/S6.70 EPS this Y-242.50% Inst Trans31.22% Short Ratio1.14 Perf Half Y-17.20%
Book/sh1.33 P/B2.14 EPS next Y28.60% ROA-38.80% Target Price- Perf Year60.45%
Cash/sh- P/C- EPS next 5Y20.00% ROE-65.80% 52W Range1.50 - 4.63 Perf YTD35.89%
Dividend- P/FCF- EPS past 5Y-16.70% ROI-95.40% 52W High-38.66% Beta1.95
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin90.20% 52W Low89.33% ATR0.16
Employees71 Current Ratio4.50 Sales Q/Q42.10% Oper. Margin- RSI (14)68.99 Volatility6.14% 6.81%
OptionableYes Debt/Eq0.00 EPS Q/Q77.90% Profit Margin- Rel Volume0.50 Prev Close2.80
ShortableYes LT Debt/Eq0.10 EarningsOct 29 AMC Payout- Avg Volume620.92K Price2.84
Recom1.40 SMA2011.70% SMA5024.65% SMA200-0.70% Volume311,790 Change1.43%
Mar-03-20Initiated Craig Hallum Buy $7.50
Sep-25-19Initiated Evercore ISI Outperform
Sep-24-19Initiated Jefferies Buy $8
Dec-18-18Initiated Laidlaw Buy $11
Dec-06-17Initiated Cantor Fitzgerald Buy $14
Jan-25-17Reiterated H.C. Wainwright Buy $15 → $18
Apr-25-16Initiated H.C. Wainwright Buy $15
Nov-10-15Initiated Stifel Buy $21
Nov-10-15Initiated JMP Securities Mkt Outperform
Nov-24-20 07:30AM  
Nov-12-20 07:30AM  
Nov-10-20 12:42PM  
Nov-03-20 11:52AM  
Oct-29-20 05:35PM  
04:01PM  
03:00PM  
Oct-22-20 07:30AM  
Sep-30-20 06:05PM  
Sep-28-20 10:30PM  
Sep-27-20 01:08AM  
Sep-23-20 10:30PM  
Sep-21-20 09:30PM  
Sep-19-20 05:14PM  
Sep-17-20 08:00AM  
Sep-16-20 11:29PM  
04:35PM  
01:05PM  
Sep-14-20 08:32PM  
11:00AM  
Sep-08-20 08:00AM  
06:30AM  
Aug-28-20 01:37PM  
Aug-04-20 09:05AM  
07:30AM  
Jul-28-20 07:30AM  
Jul-22-20 12:32PM  
Jul-07-20 07:30AM  
Jul-05-20 10:26PM  
Jul-01-20 07:30AM  
Jun-01-20 07:30AM  
May-27-20 11:34AM  
May-20-20 07:30AM  
May-18-20 10:04AM  
07:30AM  
May-15-20 06:33AM  
May-11-20 07:30AM  
May-06-20 09:35AM  
08:25AM  
07:30AM  
Apr-29-20 12:34PM  
Apr-20-20 07:30AM  
Mar-07-20 12:26AM  
Feb-27-20 08:35AM  
07:30AM  
Feb-25-20 08:55AM  
07:30AM  
06:30AM  
Feb-19-20 07:30AM  
Jan-30-20 04:30PM  
Jan-09-20 07:30AM  
Dec-16-19 07:35AM  
Nov-18-19 01:03PM  
07:30AM  
Nov-17-19 09:25AM  
Nov-12-19 07:30AM  
Nov-07-19 09:05AM  
07:30AM  
Nov-06-19 08:21AM  
Nov-05-19 03:32PM  
06:30AM  
Oct-31-19 10:33AM  
Oct-29-19 07:30AM  
Oct-23-19 10:33AM  
Oct-17-19 07:30AM  
Sep-25-19 09:04AM  
Sep-19-19 07:30AM  
Sep-03-19 07:30AM  
Aug-21-19 10:12PM  
Aug-13-19 08:45AM  
Jul-31-19 09:15AM  
07:30AM  
Jul-24-19 07:30AM  
Jul-19-19 07:30AM  
Jul-11-19 06:40AM  
Jul-01-19 07:30AM  
Jun-23-19 04:11PM  
Jun-12-19 07:30AM  
Jun-04-19 07:30AM  
May-30-19 07:30AM  
May-09-19 04:05PM  
May-06-19 05:24PM  
May-04-19 11:14PM  
May-02-19 12:23AM  
May-01-19 01:16PM  
11:12AM  
07:30AM  
Apr-26-19 09:43AM  
08:02AM  
Apr-25-19 04:01PM  
Apr-24-19 07:30AM  
Apr-18-19 10:13AM  
Apr-15-19 07:30AM  
Mar-25-19 07:30AM  
Mar-11-19 12:36PM  
07:30AM  
Mar-08-19 07:30AM  
Mar-04-19 08:58AM  
07:30AM  
Feb-27-19 07:30AM  
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILL DAVID NDirectorSep 24Buy2.138,00017,04074,896Sep 28 07:48 AM
CDK ASSOCIATES, L.L.C.10% OwnerSep 18Buy2.206,00013,2008,060,682Sep 21 09:48 PM
CDK ASSOCIATES, L.L.C.10% OwnerSep 17Buy2.251,473,3773,315,0988,054,682Sep 21 09:48 PM